News

Eli Lilly stock has delivered very strong gains over the past five years. Current checks give a mixed read on valuation, with the Discounted Cash Flow (DCF) intrinsic value estimate pointing to upside, while market based multiples look closer to fair. Eli Lilly has returned 373.6% over five years, which puts a lot of optimism into the share price and raises the bar for what counts as good value today. The expanded use of drugs like Mounjaro and Zepbound in metabolic and cardiovascular care...

Daraxonrasib, the pill touted by a former member of Congress and cancer patient as a ‘miracle drug,’ has been granted approval in patients with pancreatic adenocarcinoma.

The Food and Drug Administration cleared a blood test for identifying Alzheimer’s disease symptoms, which was developed by Roche and Eli Lilly.

Lilly is suing several US companies that are allegedly selling illegal versions of its weight loss candidate, retatrutide.

Lilly is trying to protect an experimental obesity medicine from unauthorized sellers before regulators decide whether to approve it.

Lilly said the products being sold on the black market are unverified, unapproved, and not worth the risk.

Ahead of an approval filing, the drugmaker is amping up a fight against sellers who claim to offer versions of its highly anticipated “triple-G” weight loss medicine.

Dismissal removes one legal challenge involving compounded alternatives while Novo confronts intensifying commercial competition in obesity treatments.

A Texas judge dismissed claims that the drugmakers illegally blocked access to compounded weight-loss drugs.

The new findings position Lilly to file an application for the highly anticipated medicine, but also leave some questions about the additive benefits a “triple-G” drug has on heart health.

Novo Nordisk sues LLY over high-profile ads promoting Zepbound and Mounjaro, arguing newer clinical data changes the comparison as the GLP-1 rivalry intensifies.

Novo Nordisk’s lawsuit against Eli Lilly (LLY) over alleged misleading GLP-1 advertising has put fresh attention on Lilly’s stock and raised questions about how core obesity and diabetes franchises are being marketed. See our latest analysis for Eli Lilly. Against this legal backdrop, Eli Lilly’s 1-day share price return of 2.49% and 30-day share price return of 6.99% sit within a broader upswing, with a 52.46% 1-year total shareholder return and a very large 5-year total shareholder return...

Novo Nordisk is also demanding that Eli Lilly pull its ads and pay damages.

Novo alleges that Lilly’s Zepbound advertisements compare the drug’s highest approved dose with lower doses of Wegovy.

FDA grants full approval to Eli Lilly's selpercatinib (Retevmo) for a wider group of adult and pediatric patients with RET fusion solid tumors. The decision shifts selpercatinib from accelerated to traditional approval and broadens its labeled use across multiple tumor types. The update reinforces Eli Lilly's (NYSE:LLY) position in oncology and opens new commercial and clinical avenues for the drug. Eli Lilly, known for its oncology and biopharma portfolio, now has a fully approved RET...

Eli Lilly and Company (LLY) on Tuesday received traditional approval from the US Food and Drug Admin

BIIB secures FDA approval for Leqembi Iqlik, letting early Alzheimer's patients start with a weekly at-home autoinjector instead of biweekly IV infusions.

June 30 (Reuters) - A bipartisan group of U. lawmakers has opened national security investigations into whether drugmakers Merck and AbbVie have been involved in clinical trials conducted in China that helped fuel the communist country's military capability, according ‌to letters seen by Reuters.

Eli Lilly and Company (NYSE:LLY) is one of the 12 Best Growth Stocks Trading in Oversold Territory. On June 9, the US FDA approved a new maintenance dosing regimen for Eli Lilly’s EBGLYSS (lebrikizumab-lbkz), allowing adults and children aged 12 and older with moderate-to-severe atopic dermatitis to receive a single injection once every 8 weeks. […]

Baxfendy gained FDA clearance for uncontrolled hypertension patients as AstraZeneca expands its cardiovascular and metabolic portfolio.